Enhanced working and verbal memory after lamotrigine treatment in pediatric bipolar disorder
- PMID: 20402714
- PMCID: PMC2858356
- DOI: 10.1111/j.1399-5618.2010.00792.x
Enhanced working and verbal memory after lamotrigine treatment in pediatric bipolar disorder
Abstract
Objective: To examine the treatment impact of lamotrigine on the neurocognitive profile of patients with pediatric bipolar disorder (PBD).
Method: Healthy controls (HC) (n = 24; mean age = 12.4 +/- 3.3 years) and unmedicated PBD patients with manic, mixed, or hypomanic episodes (n = 34; mean age = 13 +/- 3.1 years) were matched for IQ, age, sex, race, and socioeconomic status. A neurocognitive battery was administered at baseline and again after 14 weeks, during which PBD patients were treated with lamotrigine.
Results: Clinical symptoms improved with treatment in the patient group with significant change from baseline to follow-up on the Young Mania Rating Scale (p < 0.001) and the Children's Depression Rating Scale-Revised (p < 0.001). Global neurocognitive function improved with lamotrigine in PBD patients over time relative to that in HC, although overall performance remained impaired. Working memory and verbal memory significantly improved with treatment in patients, and deficits in these domains were no longer significantly impaired relative to HC at follow-up. Executive function significantly improved with treatment in the patient group but still lagged behind HC at follow-up. Performance on attention tests did not improve with treatment.
Conclusions: There appears to be significant improvement in cognitive abilities in PBD patients treated with lamotrigine that is most prominent in the areas of working memory and verbal memory and that occurs along with mood stabilization.
Keywords: attention; bipolar; cognition; executive functioning; lamotrigine; verbal memory; working memory.
Conflict of interest statement
MNP receives research support, unrelated to this manuscript, from NIMH, NICHD, The Dana Foundation, The American Foundation for Suicide Prevention, NARSAD Independent Investigator Award, Abbott Pharmaceuticals (study medication), and Johnson & Johnson (study medication). JAS has received research support, unrelated to this work, from NIH, GlaxoSmithKline, Johnson & Johnson, and AstraZeneca. AMP, TM, and JAC have no financial relationships to disclose.
Figures
References
-
- McClellan J, Kowatch R, Findling RL. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:107–125. - PubMed
-
- Findling RL, McNamara NK, Stansbrey R, et al. Combination lithium and divalproex sodium in pediatric bipolar symptom re-stabilization. J Am Acad Child Adolesc Psychiatry. 2006;45:142–148. - PubMed
-
- DelBello MP, Kowatch RA. Pharmacological interventions for bipolar youth: developmental considerations. Dev Psychopathol. 2006;18:1231–1246. - PubMed
-
- Pavuluri MN, O';Connor MM, Harral EM, Moss M, Sweeney JA. Impact of neurocognitive function on academic difficulties in pediatric bipolar disorder: a clinical translation. Biol Psychiatry. 2006;60:951–956. - PubMed
-
- Pavuluri MN, Schenkel LS, Aryal S, et al. Neurocognitive function in unmedicated manic and medicated euthymic pediatric bipolar patients. Am J Psychiatry. 2006;163:286–293. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources